Consensus 12-month price targets from institutional equity research analysts covering Benitec Biopharma Inc. (NASDAQ: BNTC) vary depending on clinical trial updates, but generally reflect substantial projected upside from its micro-cap/small-cap trading baseline, driven by anticipated clinical milestones within its genetic medicine and proprietary platform pipeline.